Long term tenofovir disoproxil fumarate (TDF) therapy and the risk of hepatocellular carcinoma

被引：0
|
作者：
Sievert, W. [1 ,2 ]
Strasser, S. [3 ]
Gane, E. [4 ]
George, J. [5 ]
Weilert, F. [6 ]
Flaherty, J. F. [7 ]
Dinh, P. [7 ]
Schall, R. A. [7 ]
Martins, E. B. [7 ]
Yee, L. [7 ]
Marcellin, P. [8 ]
Kim, W. R. [9 ]
机构：
[1] Monash Univ, Melbourne, Vic 3004, Australia
[2] Monash Med Ctr, Melbourne, Vic, Australia
[3] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[4] Auckland City Hosp, Auckland, New Zealand
[5] Univ Sydney, Westmead Hosp, Storr Liver Unit, Sydney, NSW 2006, Australia
[6] Waikato Hosp, Hamilton, New Zealand
[7] Gilead Sci Inc, Foster City, CA 94404 USA
[8] Hop Beaujon, Clichy, France
[9] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2013年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：53 / 54
页数：2
相关论文
共 50 条
  • [1] LONG TERM TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY AND THE RISK OF HEPATOCELLULAR CARCINOMA
    Kim, W. R.
    Berg, T.
    Loomba, R.
    Schall, R. Aguilar
    Dinh, P.
    Yee, L. J.
    Martins, E. B.
    Flaherty, J. F.
    Gurel, S.
    Buti, M.
    Marcellin, P.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S19 - S19
  • [2] ALT Levels and Risk of Hepatocellular Carcinoma (HCC) in Caucasian Chronic Hepatitis B (CHB) Patients Under Long-Term Therapy with Entecavir (ETV) or Tenofovir Disoproxil Fumarate (TDF)
    Papatheodoridis, George V.
    Dalekos, George N.
    Yurdaydin, Cihan
    Sypsa, Vana
    van Bommel, Florian
    Buti, Maria
    Luis Calleja, Jose
    Chi, Heng
    Goulis, Ioannis
    Manolakopoulos, Spilios
    Loglio, Alessandro
    Siakavellas, Spyros
    Keskin, Onur
    Veelken, Rhea
    Lopez-Gomez, Marta
    Hansen, Bettina E.
    Savvidou, Savvoula
    Kourikou, Anastasia
    Vlachogiannakos, Ioannis
    Galanis, Kostas
    Idilman, Ramazan
    Esteban, Rafael
    Janssen, Harry L. A.
    Berg, Thomas
    Lampertico, Pietro
    HEPATOLOGY, 2018, 68 : 162A - 163A
  • [3] SIMILAR RISK OF HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT DURING LONG-TERM ENTECAVIR (ETV) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS
    Papatheodoridis, George V.
    Dalekos, George N.
    Yurdaydin, Cihan
    Sypsa, Vana
    van Boemmel, Florian
    Buti, Maria
    Luis Calleja, Jose
    Goulis, Ioannis
    Manolakopoulos, Spilios
    Loglio, Alessandro
    Papatheodoridi, Margarita
    Gatselis, Nikolaos K.
    Keskin, Onur
    Veelken, Rhea
    Lopez Gomez, Marta
    Hansen, Bettina E.
    Savvidou, Savvoula
    Kourikou, Anastasia
    Vlachogiannakos, Jiannis
    Galanis, Kostas
    Idilman, Ramazan
    Esteban-Mur, Rafael
    Janssen, Harry L. A.
    Berg, Thomas
    Lampertico, Pietro
    HEPATOLOGY, 2019, 70 : 286A - 287A
  • [4] Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
    De Clercq, Erik
    BIOCHEMICAL PHARMACOLOGY, 2016, 119 : 1 - 7
  • [5] Impact of Long-Term Tenofovir Disoproxil Fumarate on Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
    Kim, W. Ray
    Loomba, Rohit
    Berg, Thomas
    Schall, Raul E. Aguilar
    Yee, Leland J.
    Dinh, Phillip V.
    Flaherty, John F.
    Martins, Eduardo B.
    Therneau, Terry M.
    Jacobson, Ira
    Fung, Scott
    Gurel, Selim
    Buti, Maria
    Marcellin, Patrick
    CANCER, 2015, 121 (20) : 3631 - 3638
  • [6] Establishing the Mechanisms of Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF) in Osteogenesis
    Lazcano, Itzel
    Patel, Niyati
    Finerty, Declan
    Ross, Ryan
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 : 355 - 355
  • [7] IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)
    Chan, Henry Lik Yuen
    Lim, Young-Suk
    Seto, Wai Kay
    Ning, Qin
    Agarwal, Kosh
    Janssen, Harry L. A.
    Pan, Calvin O.
    Chuang, Wan Long
    Izumi, Namiki
    Fung, Scott
    Shalimar
    Brunetto, Maurizia
    Flaherty, John
    Mo, Shuyuan
    Cheng, Cong
    Lin, Lanjia
    Gaggar, Anuj
    Subramanian, Mani
    Marcellin, Patrick
    Gane, Edward
    Hou, Jinlin
    Buti, Maria
    GUT, 2020, 69 : A75 - A76
  • [8] IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)
    Lim, Young-Suk
    Chan, Henry Lik Yuen
    Seto, Wai-Kay
    Ning, Qing
    Agarwal, Kosh
    Janssen, Harry L. A.
    Pan, Calvin Q.
    Chuang, Wan Long
    Izumi, Namiki
    Fung, Scott K.
    Shalimar
    Brunetto, Maurizia R.
    Flaherty, John F.
    Mo, Shuyuan
    Cheng, Cong
    Lin, Lanjia
    Gaggar, Anuj
    Subramanian, Mani
    Marcellin, Patrick
    Gane, Edward J.
    Hou, Jinlin
    Buti, Maria
    HEPATOLOGY, 2019, 70 : 126A - 127A
  • [9] Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Lee, Hye Won
    Cho, Young Youn
    Lee, Hyein
    Lee, Jae Seung
    Kim, Seung Up
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Kim, Beom Kyung
    Park, Soo Young
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (11) : 1570 - 1578
  • [10] IMPACT OF LONG- TERM TREATMENT WITH CONTINUOUS TENOFOVIR ALAFENAMIDE ( TAF) OR AFTER SWITCH FROM TENOFOVIR DISOPROXIL FUMARATE ( TDF) ON HEPATOCELLULAR CARCINOMA ( HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B ( CHB)
    Lim, Young-Suk
    Wong, Grace Lai-Hung C.
    Ahn, Sang Hoon
    Seto, Wai-Kay
    Agarwal, Kosh
    Janssen, Harry L. A.
    Pan, Calvin Q.
    Chuang, Wan Long
    Fung, Scott K.
    Shalimar
    Brunetto, Maurizia R.
    Hui, Aric Josun
    Chang, Ting-Tsung
    Lim, Seng Gee
    Abramov, Frida
    Flaherty, John F.
    Wang, Hongyuan
    Yee, Leland J.
    Kao, Jia-Horng
    Marcellin, Patrick
    Gane, Edward J.
    Buti, Maria
    HEPATOLOGY, 2023, 78 : S523 - S526
12345